These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16605279

  • 1. The burden of age-related macular degeneration.
    Schmier JK, Jones ML, Halpern MT.
    Pharmacoeconomics; 2006; 24(4):319-34. PubMed ID: 16605279
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

  • 3. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.
    Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
    [Abstract] [Full Text] [Related]

  • 4. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
    Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.
    Pharmacoeconomics; 2008 Jun; 26(1):57-73. PubMed ID: 18088159
    [Abstract] [Full Text] [Related]

  • 5. Relative cost of a line of vision in age-related macular degeneration.
    Smiddy WE.
    Ophthalmology; 2007 May; 114(5):847-54. PubMed ID: 17306878
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [Abstract] [Full Text] [Related]

  • 10. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.
    Bansback N, Davis S, Brazier J.
    Eye (Lond); 2007 Dec; 21(12):1455-63. PubMed ID: 17086167
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J.
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [Abstract] [Full Text] [Related]

  • 12. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.
    Hopley C, Salkeld G, Mitchell P.
    Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009
    [Abstract] [Full Text] [Related]

  • 13. Burden of illness of neovascular age-related macular degeneration in Canada.
    Cruess A, Zlateva G, Xu X, Rochon S.
    Can J Ophthalmol; 2007 Dec; 42(6):836-43. PubMed ID: 18026200
    [Abstract] [Full Text] [Related]

  • 14. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.
    Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.
    Value Health; 2008 Nov; 11(4):563-74. PubMed ID: 18179676
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.
    Pharmacoeconomics; 2007 Nov; 25(10):863-79. PubMed ID: 17887807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.